The Anticoagulants Market is expected to register a CAGR of 9.41% during the forecast period. Anticoagulants are used to treat and prevent blood clots which can block blood vessels (an artery or a vein) that can lead to serious complications as the clot disrupts the flow of blood to important organs and can result in heart attack and stroke.
A blood clot is a seal created by the blood to stop bleeding from wounds. Most prescribed anticoagulant is warfarin. Some of the newer types of anticoagulants are edoxaban, apixaban, dabigatran, and rivaroxaban.
According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases. Four out of 5 cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years of age.
Furthermore, increasing cases of chronic diseases, unhealthy lifestyles adopted by individuals, and growing adoption of novel oral anticoagulants (NOACs) are the key driving factors in anticoagulants market.
Key Market Trends Novel Oral Anticoagulants (NOACs) Segment is Expected to Hold Significant Market Share in the Anticoagulants Market
Novel Oral Anticoagulants (NOACs) segment holds a significant market share in the anticoagulants market and is anticipated to show a similar trend over the forecast period owing to the growing adoption of the novel oral anticoagulants (NOACs) in developing countries and high preference of NOACs over the warfarin. Novel oral anticoagulants (NOACs) are a new class of anticoagulant drugs. Moreover, these are safe (lower incidence of major bleeding), convenient to use, no interactions with food, and shorter half-life. Some of the NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban. These can be used in the prevention and treatment of atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT) and pulmonary embolism.
According to the Centers for Disease Control and Prevention (CDC), each year in the United States approximately 900,000 people ((1 to 2 per 1,000 population) could be affected with deep vein thrombosis. Moreover, about 60,000-100,000 Americans die of deep vein thrombosis. The increasing incidences of cardiovascular disorders, venous thromboembolism (VTE), and technological advancements in the development of novel products are the key driving factors in the novel oral anticoagulants (NOACs) segment.
North America Holds the Largest Share by Revenue in the Market
North America is expected to hold a major market share in the global anticoagulants market due to the high demand for innovative products, and the increasing prevalence of cardiovascular disorders in this region. According to the American Heart Association Research, approximately 2,300 Americans die due to cardiovascular diseases each day, an average of one death every 38 seconds. Furthermore, the presence of top pharma and biotech companies that are involved in the development of therapeutics and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape The Anticoagulants Market is fragmented competitive and consists of several major players. Some of the major players operating in the market include Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, GlaxoSmithKline Plc, Aspen Holdings, Sanofi, Pfizer, Inc and Portola Pharmaceuticals, Inc.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
Traditional aggregometer work on the principle of light transmission. The traditional aggregometer performs light transmission aggregometry (LTA) which was once considered as the gold standard for platelet function testing and is still used for the identification and diagnosis of platelet function defects. Traditional LTA remains the most...
Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules....
Bromodomain Containing Protein 4 - Pipeline Review, H2 2020 Summary Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation....
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis - Pipeline Review, H2 2020, provides an overview of the Deep Vein Thrombosis (Cardiovascular) pipeline landscape. Deep venous thrombosis is a...